Solventum CORP

Solventum announced robust second-quarter 2026 financial results, including a 9.5% organic sales increase and a 50.9% rise in adjusted diluted EPS, while also revealing plans to separate its Health Information Systems business.

Solventum Corporation announced its intention to separate its Health Information Systems business as part of a portfolio optimization strategy, aiming to unlock shareholder value and focus on its MedTech offerings.

Solventum Corporation announced the appointment of Neil Zieselman as Senior Vice President, Controller and Chief Accounting Officer, effective August 10, 2026.

Solventum Corporation has reached a settlement to resolve a shareholder class action lawsuit regarding its by-laws.

Solventum Corporation has adopted a new Executive Severance Plan, effective June 1, 2026, modifying severance benefits for eligible employees and executive officers.

Solventum Corporation announced the results of its annual shareholder meeting held on May 15, 2026, with all proposals passing.

Solventum Corporation's Q2 2026 Form 10-Q filing details stable revenue growth, strategic portfolio optimization, and ongoing cost-saving programs, alongside significant legal provisions and restructuring charges.

Solventum reports Q1 2026 net income of $13 million, reflecting ongoing restructuring costs and the impact of the Purification and Filtration business divestiture.

Solventum Corporation reports a significant increase in net income for Q3 2025, driven by a $1.5 billion gain from the sale of its Purification and Filtration business, alongside strategic debt reduction and a new multi-year cost savings program.

Solventum Corporation reported increased net sales for Q2 2025 but a significant decline in operating income and net income for the first six months, alongside an update on its Purification and Filtration business divestiture.

Solventum Corporation reports its Q1 2025 financial results, including a definitive agreement to sell its Purification and Filtration business to Thermo Fisher Scientific Inc.

Solventum Corporation's third quarter results show a slight increase in net sales but a decrease in operating income compared to the same period last year, following its spin-off from 3M.

Solventum Corporation's 2025 annual report highlights significant net income growth driven by a major divestiture, alongside strategic acquisitions and a multi-year restructuring program.

Solventum's 2024 10-K filing details its first year as an independent company, highlighting financial performance, strategic shifts post-spin-off from 3M, and navigating a complex regulatory environment.

Neil Craig Zieselman, SVP, Controller & CAO of Solventum Corp, received 6,911 shares of common stock on August 17, 2026.

Director Carlos Alban was granted 3,300 restricted stock units (RSUs) by Solventum Corp, vesting in May 2027.

Solventum Corp director Carrie S. Cox was granted 4,848 restricted stock units as part of standard equity compensation.

Director Susan D. DeVore was granted 3,300 restricted stock units in Solventum Corp, vesting in May 2027.

Director Shirley Ann Edwards was granted 3,300 restricted stock units by Solventum Corp, vesting in May 2027.

Director Glenn A. Eisenberg was granted 3,300 restricted stock units by Solventum Corp.

Solventum Corporation's annual shareholder meeting will take place virtually on April 30, 2025, with shareholders voting on key proposals including the election of directors, executive compensation, and the ratification of PwC as the independent auditor.

Solventum's 2025 proxy statement outlines key proposals for the annual shareholder meeting, including director elections, executive compensation, and auditor ratification, marking its first year as a publicly traded company.

Vanguard Capital Management has disclosed beneficial ownership of 10,875,310 shares, representing 6.27% of Solventum Corp's common stock as of March 31, 2026.

Independent Franchise Partners, LLP has reported an 8.85% beneficial ownership stake in Solventum Corporation, holding over 15 million shares as of December 31, 2025.

Independent Franchise Partners, LLP has reported a 7.44% beneficial ownership stake in Solventum Corporation, holding 12,899,240 shares of common stock.

3M Company disclosed a beneficial ownership of 14.75% of Solventum Corporation's common stock, retaining dispositive but not voting power.

Independent Franchise Partners, LLP has disclosed a 5.86% beneficial ownership stake in Solventum Corporation, holding over 10 million shares.